32 results on '"Manning, Michael E."'
Search Results
2. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
3. Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States
4. Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists
5. Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study
6. A phase 2 open‐label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
7. A phase 2 open‐label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
8. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
9. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
10. Garadacimab, a Factor XIIa Inhibitor for Hereditary Angioedema Prevention (VANGUARD Study)
11. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
12. Escalating Doses of C1 Esterase Inhibitor (CINRYZE) for Prophylaxis in Patients With Hereditary Angioedema
13. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
14. Inhibition of Prekallikrein for Hereditary Angioedema
15. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies
16. Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening
17. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings
18. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
19. Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks due to C1-Inhibitor Deficiency in Children
20. Subgroup Analyses From the Phase 3 HELP Study of Lanadelumab for the Prevention of Hereditary Angioedema Attacks
21. Aspirin sensitivity: a distressing reaction that is now often treatable
22. Impact of Reslizumab on Duration of Exacerbations in Patients with Severe Eosinophilic Asthma
23. Use Of Central Venous Access Devices (CVAD) And Associated Outcomes In Hereditary Angioedema (HAE) Patients: Findings From A Large United States (US) Claims Database
24. Intravenous C1-INH [C1-INH(IV)] Use Among Patients with Hereditary Angioedema (HAE) in the United States (US) and Associated Health Care Resource Utilization (HCRU)
25. Placebo-Controlled Trials of C1-Inhibitor (C1-INH) Replacement Therapy for Routine Prevention of Attacks in Patients with Hereditary Angioedema (HAE)
26. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
27. Garadacimab for the prevention of hereditary angioedema attacks: a plain language summary of the VANGUARD study
28. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
29. REACTIONS TO ASPIRIN AND OTHER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
30. Aspirin sensitivity
31. Pseudoallergic Drug Reactions
32. Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.